**Core Concept**
Bleomycin toxicity is a well-known side effect of the chemotherapeutic agent used in the treatment of various malignancies. The mechanism of bleomycin-induced toxicity involves the generation of free radicals, which lead to DNA strand scission and subsequent cellular damage. This results in the activation of cellular repair pathways, including the induction of fibroblast proliferation.

**Why the Correct Answer is Right**
Bleomycin-induced pulmonary toxicity is characterized by the hyperplasia of type II pneumocytes, which are the cells responsible for the production of surfactant in the lung. This hyperplasia is a result of the activation of the cellular repair pathways in response to the DNA damage caused by the free radicals generated by bleomycin. The repair process involves the proliferation of type II pneumocytes, which can lead to the formation of fibrotic lesions in the lung.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because bleomycin-induced toxicity does not primarily involve the hyperplasia of type I pneumocytes. Type I pneumocytes are the cells responsible for gas exchange in the lung and are not typically involved in the repair process.
**Option B:** This option is incorrect because bleomycin-induced toxicity does not primarily involve the hyperplasia of alveolar macrophages. Alveolar macrophages are involved in the clearance of inhaled particles and are not directly involved in the repair process.
**Option C:** This option is incorrect because bleomycin-induced toxicity does not primarily involve the hyperplasia of Clara cells. Clara cells are a type of non-ciliated epithelial cell found in the bronchioles and are not typically involved in the repair process.

**Clinical Pearl / High-Yield Fact**
It's essential to recognize that bleomycin-induced pulmonary toxicity can occur even at low doses and can be exacerbated by factors such as age, smoking, and underlying lung disease. A thorough history and physical examination are crucial in identifying patients at risk for bleomycin-induced toxicity.

**Correct Answer: C. Type II pneumocytes.**